SI-BONE Corporate Overview August 2025 Forward-Looking Statements This presentation contains "forward-looking statements," which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking statements often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the neg ...

Core Insights - SI-BONE, Inc. reported strong financial results for Q2 2025, with worldwide revenue of $48.6 million, a 21.7% increase from $40.0 million in Q2 2024, driven by robust procedure demand and successful product launches [5][4][7] - The company achieved a gross profit of $38.8 million, reflecting a gross margin of 79.8%, an improvement of 80 basis points compared to the previous year [6][7] - SI-BONE's net loss improved by 31.2% to $6.2 million, or $0.14 per diluted share, compared to a net loss of $8.9 million, or $0.22 per diluted share in Q2 2024 [9][7] Financial Performance - U.S. revenue for Q2 2025 was $46.4 million, a 22.8% increase from $37.8 million in Q2 2024, benefiting from strong underlying procedure demand [5][7] - Operating expenses increased by 10.0% to $45.8 million, primarily due to higher commercial activity and new product rollouts [8] - Adjusted EBITDA was positive at $1.0 million, improving from an adjusted EBITDA loss of $2.7 million in the same period last year [9][7] Operational Highlights - The company reported 1,440 active U.S. physicians, representing a growth of approximately 25% [7] - The trailing 12-month average revenue per territory increased by approximately 23% to $2.1 million [7] - SI-BONE launched the iFuse TORQ across Europe in July 2025, with initial cases performed in multiple countries [7] Leadership Update - Tony Recupero, President of Commercial Operations, announced his retirement effective February 15, 2026, transitioning to an advisory role [7][4] - Nikolas Kerr has been appointed as the new Chief Commercial Officer, effective February 16, 2026 [7][4] Financial Guidance - SI-BONE expects 2025 worldwide revenue to be in the range of $195 million to $198 million, implying year-over-year growth of approximately 17% to 18% [11][12] - The company estimates full-year 2025 gross margin to be between 78.5% and 79.0% and anticipates operating expenses to grow at approximately 10% at the midpoint of the revenue guidance [11][12]

Company Participation - SI-BONE, Inc. will participate in the 2025 Goldman Sachs 46 Global Healthcare Conference in Miami Beach, FL, hosting a fireside chat on June 10, 2025, at 8:20 a.m. Pacific Time [1] Company Overview - SI-BONE is a global leader in developing technologies for surgical treatment of sacropelvic disorders, having pioneered minimally invasive SI joint surgery in 2009 with the iFuse Implant System [3] - The company has supported over 4,500 physicians in performing more than 120,000 procedures, backed by over 160 peer-reviewed publications, including two randomized controlled trials [3] - SI-BONE has expanded its offerings to adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation, and pelvic trauma [3]

Company Overview - SI-BONE, Inc. is a medical device company focused on addressing sacropelvic disorders and is recognized as a global leader in developing surgical technologies for these conditions [3] - The company pioneered minimally invasive SI joint surgery in 2009 and has supported over 4,500 physicians in performing more than 120,000 procedures [3] - SI-BONE has established a strong clinical evidence base, including two randomized controlled trials and over 160 peer-reviewed publications [3] Upcoming Event - SI-BONE will participate in the 2025 BofA Securities Healthcare Conference in Las Vegas, with a fireside chat scheduled for May 13, 2025, at 8:40 a.m. Pacific Time [1] - Investors can listen to the conference call by registering online, and a live audio webcast will be available on the company's website [2]

Financial Performance - SI-BONE achieved a worldwide revenue growth of 24.9% reaching $47.3 million in 1Q25[8] - U S revenue grew by 26.6% to $44.8 million in 1Q25[8] - The company reported a gross margin of 79.7%, an improvement of 80 basis points[8] - Adjusted EBITDA turned positive at $0.5 million, a 112% year-over-year improvement[8, 15] - The company expects to have $144.4 million in cash and equivalents[16] Physician Engagement and Procedure Volume - SI-BONE added a record 300 U S physicians in 1Q25[6] - There was a 27.1% growth in U S active physicians[8] - U S procedure volume increased by approximately 27% from 4,000 in 1Q24 to 5,100 in 1Q25[10] - The U S active physician base grew by approximately 27% from 1,100 in 1Q24 to 1,400 in 1Q25[12] Product and Market Opportunity - The company is developing a third breakthrough-designated device, iFuse TORQ TNT[6] - SI-BONE is pursuing a proposed New Technology Add-On Payment (NTAP) of $3,960 for iFuse TORQ TNT[6] - The total U S addressable market for SI-BONE's products is estimated to be over $3.5 billion, with less than 10% currently penetrated[21, 29] Future Outlook - The company updated its 2025 worldwide revenue guidance to $193.5 - $197.5 million, implying a growth of approximately 16%-18%[19, 20]

Financial Performance - SI-BONE achieved a worldwide revenue growth of 24.9% reaching $47.3 million in 1Q25[8] - U S revenue grew by 26.6% to $44.8 million in 1Q25[8] - The company reported a gross margin of 79.7%, an improvement of 80 basis points[8] - Adjusted EBITDA turned positive at $0.5 million, a 112% year-over-year improvement[8, 15] - The company expects to have $144.4 million in cash and equivalents[16] Physician Engagement and Procedure Volume - SI-BONE added a record 300 U S physicians in 1Q25[6] - There was a 27.1% growth in U S active physicians[8] - U S procedure volume increased by approximately 27% from 4,000 in 1Q24 to 5,100 in 1Q25[10] - The U S active physician base grew by approximately 27% from 1,100 in 1Q24 to 1,400 in 1Q25[12] Product and Market Opportunity - The company is developing a third breakthrough-designated device, iFuse TORQ TNT[6] - SI-BONE is pursuing a proposed New Technology Add-On Payment (NTAP) of $3,960 for iFuse TORQ TNT[6] - The total U S addressable market for SI-BONE's products is estimated to be over $3.5 billion, with less than 10% currently penetrated[21, 29] Future Outlook - The company updated its 2025 worldwide revenue guidance to $193.5 - $197.5 million, implying a growth of approximately 16%-18%[19, 20]

Core Insights - SI-BONE, Inc. will report its financial results for Q1 2025 on May 5, 2025, after market close, with a conference call scheduled for 1:30 p.m. Pacific Time [1] - The company is a leader in developing technologies for surgical treatment of sacropelvic disorders, having supported over 4,300 physicians and performed over 115,000 procedures since 2009 [3] Company Overview - SI-BONE has pioneered minimally invasive SI joint surgery and has a strong clinical evidence base, including two randomized controlled trials and over 160 peer-reviewed publications [3] - The company has expanded its offerings to adjacent markets, including adult deformity, sacropelvic fixation, and pelvic trauma [3] Investor Information - Investors can listen to the conference call by registering online, and a live audio webcast will be available on the company's website [2] - The webcast will be archived for at least 90 days for replay [2]